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Abstract
Organism homeostasis is regulated through the tri-directional relationships 
between immune, endocrine, and nervous systems. These relationships are estab-
lished by a complex network of chemokines, cytokines, hormones (peptide and 
non-peptide), neurotransmitters, and neurohormones that act onto its target cells, 
through common receptors. Despite initial attribution of the exclusive action of 
each molecule group (neurotransmitters, hormones, and cytokines), to the func-
tion of one specific system (nervous, endocrine, and immune, respectively), ligand 
and receptor pleiotropy and redundancy showed the multidirectional communica-
tion between systems. Cancer and metabolic and autoimmune diseases get estab-
lished when homeostasis is disrupted. These interactions act in different disease 
levels, in cancer, since initial immunosurveillance phase, until immunosubversion 
and metastasis, in all cases is crucial for tumor development, cancer outcome, and 
patient prognosis.
Keywords: neuroimmunoendocrine network, breast cancer, 
neuroimmunoregulation, endocrinoimmune regulation, tumor, cytokines, steroids, 
neurotransmitters
1. Introduction
Cancer is one of the most common health issues worldwide. According to the 
World Health Organization (WHO), in 2018 18,078,957 new cases and 9,555,027 
related deaths were reported. Breast cancer is the second leading cancer, after lung 
cancer, but is the first in women incidence and prevalence [1]. An estimation made 
in 2009 calculated that one out of eight American women could develop breast 
cancer in their life course [2].
There are several risk factors associated with breast cancer. The first and most 
important is gender; as mentioned before, women get breast cancer more often than 
males. Other risk factors are early menarche, first terminal pregnancy after 30 years 
old, late menopause, nulliparity, no breastfeeding, overweight or obesity, family 
or personal history of breast cancer, alcohol abuse, consumption of hormone oral 
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contraceptives or menopausal hormone therapy, and environmental pollution with 
compounds such as bisphenols and phthalates, among others [3–5].
To classify breast cancer, the actualized TNM anatomical staging system catego-
rizes primary tumor (T), regional lymph node invasion (N), and distant metastases 
(M), to determine the actual stage group of breast cancer. This classification is very 
useful, not only for diagnosis and prognosis but also for treatment. In addition to 
the anatomical staging system, factor-based prognostic stage groups that include 
tumor grade (histological), hormone receptor status, and a multigene panel status 
(when is available) were added in the 2017 TNM meeting [2, 3, 6].
Hormone receptor status takes into account the presence of estrogen receptor 
(ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 
(HER-2) in tumor mammary cells. There are some characteristics that determine 
the status of the tumor, such as anatomical localization, tumor grade, hormone 
receptor status, and, with it, the prognostic and treatment of breast cancer [6].
A normal breast is composed of mammary glands (lobules and ducts), fibrous 
connective and adipose tissues, blood and lymph vessels, lymph nodes, nerves, and 
ligaments [7]. Duct branches form each mammary gland epithelium whose caliber 
is decreased until it forms ductules that flow into lobes [7, 8]. The epithelium is 
formed by luminal epithelial cells and basal epithelial cells, also known as myoepi-
thelial cells, adjacent to the basement membrane [9]. Proliferation and apoptosis of 
mammary epithelia are regulated by the extracellular matrix (ECM) signals [10]. 
Either lobules or ducts can become dysplastic and eventually neoplastic, a phe-
nomenon also regulated by ECM, and adjacent cell interactions, including stromal, 
Figure 1. 
Nervous regulation during breast tumor growth and metastasis. Sympathetic fibers and blood vessels infiltrate 
tumor and are responsible for tumor communication with the nervous system. Sympathetic fibers release 
norepinephrine in tumor, which binds to β2-adrenergic receptor in the tumor cell membrane and activates 
adenylate cyclase through G-protein-coupled receptor subunit α. AC promotes ATP-cAMP conversion, and cAMP 
activates protein kinase A and exchange protein activated by adenylyl cyclase. PKA phosphorylates β-adrenergic 
receptor kinase, CREB, and GATA1 transcription factors. BARK recruits β-arrestin, inhibits β-adrenergic 
signal, and activates Src kinase, which in turn activates STAT3 and downstream focal adhesion kinase. FAK 
enhances migration. CREB, GATA1, and STAT3 promote VEGF, IL-6, IL-8, and MMP-9 expression, enhancing 
angiogenesis, migration, and invasion. In the other pathway activated through cAMP, EPAC also promotes 
cell migration. Stress stimulates hypothalamic-pituitary-adrenocortical axis, and the hypothalamus secretes 
corticotropin-releasing factor (CRF) that stimulates the adrenocorticotropic hormone (ACTH) secretion into blood 
vessels and systemic circulation. ACTH in adrenal gland cortex stimulates cortisol release. In tumor, cortisol binds to 
glucocorticoid receptor (GCR) in breast cancer cells and promotes the expression of MAPK phosphatase-1 (MKP1) 
and serine/threonine protein kinase 1 (SGK1) and other genes related to cell survival and apoptosis protection.
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vascular, fibroblasts, and immune cells, may favor the transformation and uncon-
trolled proliferation of cells in the breast tissue.
In breast cancer progression, there are three phases: benign disease and nonin-
vasive and invasive cancer (Figure 1). By definition, benign disease and noninva-
sive cancer share the same condition, where transformed cells do not trespass the 
basal membrane but are differentiated by histological grade. An example of this is 
the lobular carcinoma in situ, classified as a benign tumor, with associated risk in 
developing carcinoma [6]. On the other hand, in the invasive cancer, cells migrate 
through basal membrane to stromal breast and/or adjacent tissues and organs [11].
Several interactions determine different outcomes in tumor development, 
including the interactions among nervous, immune, and endocrine systems with 
the tumor. Next, we described the overall function of these systems in breast cancer 
and finally the interactions between them.
2. System interactions in breast cancer
2.1 The role of the nervous system on tumor growth and metastasis
Nervous regulation during cancer is mainly mediated through the sympathetic 
nervous system (SNS) and the hypothalamic-pituitary-adrenocortical (HPA) axis [12].
2.1.1 Sympathetic nervous system
The sympathetic nervous system regulates the organism’s vital involuntary 
functions and is in charge of the “fight-or-flight” response in danger and stressful 
situations and modulates the connection between the central nervous system and 
immune system [13].
SNS nerve fibers emerge from the thoracolumbar spinal cord, innervate 
different tissues, and produce norepinephrine [12, 14]. Nowadays, it is known 
that sympathetic nerve fibers innervate the bone marrow, thymus (primary 
lymphoid organs), spleen and lymph nodes (secondary lymphoid organs), and 
mucosa- (MALT), bronchus- (BALT), and gut- (GALT) associated lymphoid 
tissues [15–17]. Epinephrine arrives to the target tissue through blood circulation 
after being produced in the adrenal gland. Both norepinephrine and epinephrine 
bind with different affinities to adrenergic receptors α (α1/α2) and β (β1/β2/β3) in 
target cells in different tissues and organs, such as the heart, brain, adipose tissue, 
mammary gland, ovaries, prostate, lymphoid tissue, bones, and different types of 
cancer cells [13, 14].
These adrenergic receptors are expressed differentially. In smooth muscles α1AR 
and α2AR can be found, although the latter also is expressed in platelets and neu-
rons [14]. Regarding β receptors, of which noradrenaline is the main ligand, β1AR 
can be found in the adipose tissue and cardiac muscle. And β2-adrenergic receptors 
(β2ARs) are expressed in tumor and immune cells, in the heart, lung tissue, and 
smooth muscle. At least, β3AR can be found in the adipose tissue. Either β1AR, β2AR, 
or β3AR activates cAMP and in turn stimulates protein kinase A (PKA) [14].
2.1.2 Adrenergic signaling in tumors
β2AR expression has been detected in breast cancer cell lines, with different 
densities among them [18], and also in human breast tumor biopsies [19, 20]. 
Therefore, β2AR expression should be considered if a β2AR agonist treatment is 
going to be performed [21].
Tumor Progression and Metastasis
4
It is known that β2AR signaling regulates proliferation and tumor cell invasion; 
this is evidenced with β2AR blockers and the associated beneficial effect in breast 
cancer recurrence and bone, lung, and brain metastasis [13, 22]. Interestingly, 
primary TN tumor cells expressed lesser β2AR mRNA and protein than TN brain 
metastatic cells from primary breast tumor; these metastatic cells exhibited 
increased proliferation and migration. In vivo and in vitro, invasive and metastatic 
potential of these cells was diminished when treated with propranolol [22].
There have been different mechanisms described that regulate invasion and 
metastasis through β2AR signaling in tumor cells. Norepinephrine, epinephrine, 
or agonists bind β2AR and activate adenylate cyclase (AC) through G-protein-
coupled receptor subunit α (Gαs). AC activation promotes ATP-cAMP conversion 
(Figure 1) and Ca2+ intracellular increase [23]. In highly metastatic breast tumor 
cells (MDA-MB-231HM), another G-protein subunit, Gβγ, also promotes intra-
cellular Ca2+ augmentation through β2AR signaling. Either through Gβγ or Gαs, 
cAMP activates effector PKA and exchange protein activated by adenylyl cyclase 
(EPAC) and inhibits pERK1/pERK2; therefore, cell proliferation is mediated 
independently by ERK phosphorylation [23]. PKA phosphorylates CREB/ATF, 
GATA1 transcription factors, and β-adrenergic receptor kinase (BARK). BARK 
recruits β-arrestin which activates Src kinase, and this activates STAT3 [24]. Focal 
adhesion kinase (FAK) activated by STAT3 enhances migration and apoptosis 
resistance. CREB/ATF, GATA1, and STAT3 promote VEGF, IL-6, IL-8, and MMP-9 
expression and enhance angiogenesis, migration, and invasion (Figure 1) [24]. 
Meanwhile, in breast tumor cells (MCF-7 and MDA-MB-231) treated with an 
EPAC inhibitor (ESI-09), migration inhibition was found associated with mis-
localization of the A-kinase anchoring protein 9 (AKAP9); therefore, EPAC also 
promotes cell migration [25].
Another way in which β2AR signaling stimulates tumor growth is through 
promoting DNA damage and p53-associated apoptosis suppression [26].
2.1.3 Tumor innervation
During tumor initial innervation, nearby healthy tissue provides sympathetic 
fibers that infiltrate the periphery of the growing tumor [27], in response to neu-
rotropic factors secreted by tumor cells, such as neurotrophic growth factor (NGF) 
[28] and brain-derived neurotrophic factor (BDNF) [29]. These factors increase 
nerve fiber growth and thereby tumor innervation [28]. Tumor innervation is 
associated with vasculature; therefore, together with nerve fibers, blood vessels go 
through the tumor mass [30] (Figure 1). Sympathetic innervation in tumor is the 
main catecholamine source [30, 31]; this is evidenced because its local concentra-
tion is higher than plasma [31]. In this sense, innervation is a feature of tumor 
microenvironment associated with tumor aggressiveness [28].
Therefore, β-receptor antagonists could have an important role in the develop-
ment of new therapies that diminish metastasis risk and promote a slow tumor 
progression.
2.1.4 HPA axis
The HPA axis also plays an important role in stress response in mammals. In the 
hypothalamus, the paraventricular nucleus neurons secrete corticotropin-releasing 
factor into hypophyseal portal blood. CRF stimulates the release of adrenocortico-
tropic hormone by the anterior pituitary gland, to the blood vessels and systemic 
circulation. When ACTH reaches adrenal glands, the cortex stimulates the corticos-
terone production (in rodents) or cortisol (humans) (Figure 1) [32].
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Cortisol and corticosterone (glucocorticoids) exert their effects through gluco-
corticoid receptor. Different immune and breast cancer cells express this receptor, 
and glucocorticoids exert different effects in these cells.
GCR in breast cancer cells, especially in triple-negative lines (MDA-MB-231), 
promotes the expression of genes related to cell survival and apoptosis protec-
tion, for example, MAPK phosphatase-1 and serine/threonine protein kinase 1 
(Figure 1) [33, 34]. In addition, the activation of the GCR induces the expression 
of genes related to cell survival, adhesion, and EMT in a premalignant breast [35]. 
Correspondingly, in xenograft MDA-MB-231 breast tumors in mice pre-treated 
with systemic dexamethasone, the paclitaxel treatment effect was inhibited [36]. 
Therefore, glucocorticoids protect breast cancer cells from apoptosis and enhance 
their survival capabilities, favoring tumor growth.
2.1.5 Stress and tumor growth
Stress is largely linked to cancer development. Stressor exposition and SNS 
activation promote noradrenaline release into the tumor that regulates tumor pro-
gression [30]. In animals under social isolation (a stress experimental model), there 
is an increased tumor size and reduced survival [37]. Also in other stress models, 
increased tumor progression and metastasis have been observed [38, 39].
During metastatic establishment, β2AR overexpression enhances cell prolifera-
tion and invasion, to ensure metastatic establishment, and, maybe, that is why in 
primary tumor resection, the surgery induces stress and releases norepinephrine 
and epinephrine that enhance tumor metastasis. Thus, the use of treatments that 
antagonize the effect of these neurotransmitters may reduce metastasis [22].
Thus, nervous control of tumor growth is regulated by the sympathetic and 
HPA systems. The sympathetic regulation is via tumor innervation with sympa-
thetic fibers and the adrenergic signaling in tumor, through local and peripheral 
catecholamine (epinephrine and norepinephrine) production and the β2AR expres-
sion in tumor and immune cells. Meanwhile, HPA system regulates glucocorticoid 
production, which enhances tumor cell survival and downmodulates inflammatory 
response, thus enhancing tumor growth and metastasis (Figure 1).
3. Immune response in mammary tumors
Tumorigenesis usually courses a slow development during years, and the 
immune response depends on the different stages of the disease and the tumor 
microenvironment [40].
Every day, immune cells detect and destroy transformed cells, in a phenomenon 
called immunosurveillance. But, when transformed cells evade elimination mecha-
nisms (immunoescape), survive and proliferate. At this point, tumor can remain in 
a state of dormancy, partially by the action of immune cells, but when the balance 
between stromal, immune, and tumor cells with their secretory products leads to 
local immunosuppression, the immunosubversion is established, and the tumor 
grows (Figure 2) [41, 42].
3.1 Immune innate cells in mammary tumors
3.1.1 Dendritic cells
Dendritic cells are antigen-presenting cells (APCs) that recognize, uptake, process, 
and present antigens to different cells including T cells. In the immunosurveillance 
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phase, dendritic cells resident in the breast tissue sense and capture different antigens 
released by transformed cells and then migrate to draining lymph nodes, where, as 
a mature cell, antigens to naïve T cells are present [43–45]. After the activation and 
subsequent proliferation, the CD8+ T and CD4+ T cells migrate to the site where trans-
formed neoplastic cells reside. The cytotoxic response is carried out mainly by CD8+ T 
cells and NK cells, which detect and induce apoptosis to transformed cells; meanwhile, 
CD4+ T helper cells produce cytokines and chemokines that modulate the immune 
response and recruit other immune cells (Figure 2).
Two lineages of dendritic cells are responsible for T-cell priming. The first are 
DC1s that express chemokine receptor CXR1 and present antigens through MHC-I 
Figure 2. 
Immune response in breast tumor development. (1) In immunosurveillance, breast tissue-resident 
conventional dendritic cells (cDC) capture antigens released by transformed cell after recognition and 
destruction by cytotoxic cells (NK cells). cDC migrate to peripheric lymph node and as DC type 1 (DC1) 
or DC type 2 (DC2) present antigens to CD8+ T cells or CD4+ T cells, respectively. In lymph nodes T 
follicular cells activate B lymphocytes into plasma (antibody producer) or B memory cells. After the 
activation and subsequent proliferation, CD8+ T cytotoxic and CD4+ T helper cells migrate. Cytotoxic 
cells induce apoptosis to transformed cells, and T helper cells produce cytokines and chemokines to enhance 
cytotoxic effect. (2) In the equilibrium state, transformed cells evade immune recognition and proliferate to 
hyperplasia (benign disease) and eventually to ductal carcinoma in situ (DCIS). In these phases immune 
cells are recluted, and cytotoxic cells (CD8+, neutrophils, and eosinophils) may eliminate transformed cells 
in an equilibrium phase. Indirectly, other cells enhance cytotoxic response, for example, M1 macrophages 
produce IL-12 that enhances dendritic cell antigen presentation to CD8+ cells. Also mast cells MHC-I+ 
stimulate CD8+ T-cell proliferation. (3) In immunosubversion and metastasis, when invasive ductal 
carcinoma is established, tumor dendritic cells (tDC) are induced through IL-10, vascular endothelial 
factor (VEGF), prostaglandin E2 (PGE2), hypoxia, and lactic acid and by direct contact with tumor 
CTLA4+. tDC produce IL-10, which in turn induces their own expansion as well as T regulatory cell 
(Tregs) proliferation and the inhibition of effector CD4+ and CD8+ T cells, Th1 differentiation, and CD8+ 
T cells function. Also, IL-10, D vitamin, and cortisol activate M2. M2 macrophages produce IL-4, IL-10, 
IL-13 (that feedback M2 generation), NGF, and TGF-β that with IDO inhibit cytotoxic NK function. 
Mast cells secrete VEGF, tryptase, chymase, and IL-8 that enhance metastasis to different organs (lung and 
bone). Neutrophils may enhance metastasis because they form premetastatic niches that promote tumor cell 
migration and metastasis establishment.
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preferentially to CD8+ T cells. The second are the DC2s that express CD172a and 
MHC-II (high), to activate CD4+ T cells [43]. DC1s can be lymphoid-resident DC1s 
(CD8α in mice) or migratory DC1s (CD103+ in mice), being the latter mentioned 
as the main subset of DC that can induce a strong cytotoxic response against tumor 
through the activation of CD8+ T cells [46]. Meanwhile, DC2s (CD11+ in mouse) 
seem to fail in tumor antigen presentation to CD4+ T cells in lymph nodes, but it is 
unclear why. A possibility is an inadequate process of antigen or the nature of tumor 
antigen. These DC2s cells can be tolerogenic, because they cannot generate an 
adequate activation and stimulation [43].
Three features lead to the induction of suppressive or tumor phenotype DC. The 
first is the presence of tumor cell neoantigens that leads eventually to immuno-
escape and the failure of immunosurveillance. The second is the degree of DC 
maturation, in which immature DC acquire a tolerogenic phenotype and generate 
regulatory T cells. And the third is related to the immune suppression in the tumor 
microenvironment mediated by other cells and soluble factors. The balance of 
stimulatory and suppressive signals determines tumor progression and is related to 
cell tumor phenotype and the interaction among cells [43].
There are many tumor microenvironment factors that suppress DC activation 
in vitro, for example, IL-10, vascular endothelial factor, prostaglandin E2, hypoxia, 
and lactic acid [47]. Another important interaction is when breast tumor and DC 
are in contact. Chen et al. showed a decreased expression of CD40, CD80, CD86 
(costimulatory molecules), HLA-DR, and CD83 and a reduced production of 
IFN-γ, TNF-α, IL-1β, IL-2, IL-6, and IL-12, in lipopolysaccharide (LPS)-stimulated 
human DC, when co-cultured with CTLA4+ breast cancer cells. These suppressive 
DC inhibit CD4+ and CD8+ T-cell proliferation, Th1 differentiation, and cytotoxic 
lymphocyte (CTL) function (Figure 2) [48].
When a transformed cell escapes of the immune recognition and destruction, 
and starts proliferating, it recruits different immune cells and promotes a pro-
tumoral and suppressor microenvironment. Among these tumor-recruited cells are 
DCs, which migrate to local lymph nodes and present tumor antigens to lympho-
cytes. Meanwhile some recruited DC go to lymph nodes, and another subset of DC 
remains in tumor and developed suppressor functions through the direct inhibition 
of the local activation of CD4+ and CD8+ T cells or through suppressive cytokine 
production (IL-10) (Figure 2) [43, 49]. These DC may have an important role in 
lymphocyte priming in tumor, associated with the presence of tertiary lymphoid 
structures (TLS) in breast tumors, specially placed in stroma and with naïve T cells 
in tumors that are activated in situ [50, 51].
3.1.2 Neutrophils
Neutrophils are polymorphonuclear (PMN) cells and the most abundant leuko-
cyte in human. These cells are responsible for host defense to bacterial, fungal, and 
viral infections and support wound healing [52]. Neutrophils can phagocyte, form 
neutrophil extracellular traps (NETs) to eliminate invasive microorganisms, and  
synthesize and store in cytoplasmic granules neutrophil elastase, cathepsin G, 
proteinase 3, neutrophil collagenase (MMP-8), gelatinase B (MMP-9), reactive 
oxygen species (ROS), and antimicrobial peptides [53–55]. Through chemotactic 
stimuli, neutrophils arrive to the inflammation site and phagocyte the invading 
microorganism. Thereafter, cytoplasmic granules in the neutrophil get fused with 
the phagolysosome where the microorganism is destroyed [52]. Under adverse 
circumstances, neutrophil can release proteinases through microbursts, to the 
extracellular space, or produce NETs to fix the microorganisms, stop their migra-
tion, and concentrate on toxic factors [56].
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Some authors mentioned a neutrophil polarization similar to classical activated 
macrophages (M1) and alternative activated macrophages (M2), named N1 and N2; 
also, neutrophils present different degrees of activation, and according to it, there 
are four types of PMN: naïve circulating, mildly activated, activated (acute inflam-
mation), and highly activated (sepsis, unsuccessful phagocytosis). Among mildly 
activated neutrophils are tumor-associated neutrophils (TANs) that in mice express 
CD11b+ and Ly-6Ghi markers [52, 57].
Cellular cytotoxic role in cancer is traditionally associated with cytotoxic T 
cells, NK cells, and macrophages, and little attention is focused on neutrophils, 
but nowadays, reports are linking neutrophils to different stages of cancer [56]. 
Naïve neutrophils are recruited to the tumor, mainly by macrophages, and display 
the same repertory to kill a microorganism for the destruction of a tumor cell, and 
eventually a pro-host or pro-tumoral effect in situ is developed (Figure 2) [52].
The presence or absence and quantity of neutrophils within the tumor, associated 
with tumor type, determine the prognostic of the disease [57]. In an orthotopic murine 
model of breast cancer with 4T1 (metastatic cells) and 4T07 (nonmetastatic cells), 
more neutrophils within 4T1 tumors in comparison to 4T07 tumors were detected. 
Also in 4T1 tumors, higher mRNA expression of CXCL1, a neutrophil-recruiting 
chemokine, was detected [58]. For example, a pre-metastatic niche has been reported 
in remote organs, where neutrophils come together and shape a microenvironment 
that favored the migration of tumor cells (Figure 2) [59]. One of the mechanisms that 
shape a pre-metastatic niche could be mediated by NETs, as has been demonstrated 
in an experiment where neutrophils were co-cultured with 4T1 cells in a transwell 
chamber assay and produced more NETs than neutrophils co-cultured with 4T07 cells. 
In the same report, authors proved the presence of NET structures located next to 4T1 
cells, which was assumed to contribute to support metastasis [58].
3.1.3 Eosinophils
Eosinophils are granulocyte cells that can be found in the spleen, lymph nodes, 
thymus, and gastrointestinal tract [60] and are able to phagocyte and act as anti-
gen-presenting cell in lymph nodes, through the expression of major compatibility 
complex and costimulatory molecules (CD40, CD80, CD86) [61]. Furthermore, 
eosinophils produce cytokines, chemokines, growth factors, lipid mediators, and 
cytotoxic granules (Table 1).
Eosinophils are usually related to parasitic infections, especially helminthiases, 
in which eosinophilia is a characteristic feature. But recently their role in cancer has 
become relevant. Depending on its cytokine profile production, a new classification 
of eosinophils has been proposed; the eosinophils that secrete Th1 cytokines (IL-8, 
TNF-α, and IFN-γ) are called E1, and the ones that produce Th2 cytokines (IL-4, 
IL-5, and IL-13) are E2. Despite this classification, in breast cancer it is unknown 
if the eosinophils secrete any of those cytokines, although blood eosinophilia is 
related to a good or poor prognostic of the disease, depending on the cancer type 
[79]. Related to eosinophil infiltration into the breast cancer tumor, the presence of 
eosinophils is one indicator of increased survival, maybe because these cells partici-
pate in host-tumor interactions and because of their cytotoxic activity [83].
3.1.4 Mast cells
Mast cells originate in bone marrow, then circulate and migrate to tissues, and in 
nearby blood vessels mature into effector cells, in which along with DC and macro-
phages, are the first cells to recognize and interact with pathogens or allergens [84, 85]. 
Inside mast cells there are granules with preformed substances that included histamine 
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General functions Cancer-related features
Cytokines IL-8 Supports endothelial cell 
proliferation and survival 
[62]
Breast cancer tissue 
expresses higher 
concentrations of IL-8 
than normal  
tissue[63]
TNF-α Pro-inflammatory 
cytokine
Chronic expression 
sustains breast tumor 
growth [64]
IL-4 Promotes a Th2 profile, 
B-cell differentiation, and 
IgE isotype switch
IL-5 Stimulates proliferation, 
differentiation, 
recruitment, and 
activation of eosinophils 
[65]
IL-13 Regulates IgE synthesis 
and mucus production 
[66]
A higher tumor stage  
correlates with higher 
serum levels and  
lymph node metastasis 
[67]
Chemokines CCL3, CCL5, CCL11, 
CCL24; CXCL8, CCL7
Chemoattractant for 
eosinophils
Recruitment of 
eosinophils to tumor
CCL3, CCL5, CCL11, 
CCL17, CCL22, CCL23; 
CXCL1, CXCL5, CXCL8, 
CXCL9, CXCL10, CXCL11
Chemokines secreted 
by eosinophils to recruit 
other immune cells
Recruitment of immune 
cells to tumor
Growth 
factors
TGF-α In mammary mouse 
tissue, overexpression 
of TGF-α induces 
hyperplasia and 
proliferation [68]
TGF-β Regulates cellular 
differentiation, 
proliferation, apoptosis, 
and migration [69]
In early stages suppresses 
tumor progression but in 
late stages favors tumor 
growth [69]
VEGF Promotes angiogenesis Promotes tumor 
angiogenesis
Lipid 
mediators
Leukotrienes Pro-inflammatory Elevated levels in colon, 
pan creatic, and prostate 
cancer [70]
Prostaglandin
E2
Shifts Th2 response and 
downregulates CD8+ 
T-cell activity and tumor 
cell antigen presentation 
[71]
Promotes tumor growth 
in breast cancer
Is associated with poor 
prognosis [72]
Thromboxanes Overexpression is 
associated with poor 
prognosis in urothelial 
cancer [73]
Lipoxins (lipoxin A4) Suppressing the 
polarization of B 
regulatory cells [74]
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(vasodilator), heparin (anticoagulant), serotonin, dopamine, tryptase, and chymase. 
The mast cell activation stimulates the production of leukotrienes and cytokines (e.g., 
TNF-α) and the cell degranulation [86].
Mast cells may perform both immunosuppressive and inflammatory functions 
depending on the interaction with the effector or regulatory immune cells [85]. For 
example, the expression of MHC-II in mast cells can be induced by the exposure of 
LPS and IFN-γ, and the interaction of MHC-II-expressing mast cells with effector T 
cells induces the expansion of Treg cells; meanwhile, mast cells expressing MHC-I 
can enhance the proliferation of CD8+ T cells [87, 88]. Besides direct contact with 
T cell, an alternative activation mechanism could be the mast cell production of 
IFN. This cytokine enhances the proliferation of T cells, depending on the number 
of mast cells within the microenvironment, for example, at low numbers prolifera-
tion is enhanced, but in higher numbers proliferation is inhibited, in a mechanism 
mediated by the H1 histamine receptor [89, 90].
On the other hand, for naïve B-cell survival and activation and for plasma cell 
proliferation and differentiation, mast cells interact with B cell through superficial 
CD40L. Also for the B-cell synthesis of IgE, the secretion of IL-4 and IL-13, among 
others, by mast cells is necessary [85].
Despite mast cells releasing angiogenic factors, as VEGF, chymase, tryptase, 
heparin, fibroblast growth factor-2 (FGF-2), IL-8, TGF-β, and nerve growth factor, 
the inhibition of mast cell degranulation did not change the mammary tumor 
vascularization, but that does not mean that degranulation may enhance angio-
genesis [91]. In this regard, a study informed that tryptase did not stimulate the 
proliferation of MDA-MB-231 breast cancer cells but indeed enhances its migra-
tion and invasion [92]. In malignant breast carcinomas, there are more tryptase-
containing mast cells detected through immunohistochemistry assay than that in 
benign lesions [93]. Given the prominent angiogenic character of mast cells, to date, 
their presence has not been strongly associated with the enhancement of the tumor 
General functions Cancer-related features
Cytotoxic 
granules
Eosinophil cationic protein Tissue remodeling, 
suppression of T-cell 
proliferation, mast cell 
degranulation, and 
secretion of airway  
mucus [75]
Proliferation inhibition 
in colorectal carcinoma 
and oral squamous cell 
carcinoma cell lines, via 
osmotic lysis [76, 77]
Major basic protein Tissue damage Cytotoxic effect in human 
cancer cell lines [78]
Eosinophil-derived 
neurotoxin
Cytotoxic activity and 
chemoattractant of DC, 
monocytes, neutrophils, 
mast cells, and T cells [79]
Cytotoxic activity in 
colorectal carcinoma cell 
line [80]
Eosinophil peroxidase Related to inflammatory 
tissue injury [81]
Absent in normal breast 
tissue but present in breast 
cancer tumor stroma [82]
CCL5 or RANTES, regulated on activation normal T expressed and secreted; CCL3 or MIP-1α, macrophage 
inflammatory protein; CCL7 or MCP-3, monocyte-specific chemokine protein; TGF-α, transforming growth factor 
α; TGF-β, transforming growth factor β; VEGF, vascular endothelial cell growth factor; GM-CSF, granulocyte 
macrophage colony-stimulating factor
Table 1. 
Functions and related cancer features of cytokines and chemokines.
11
Neuroimmunoendocrine Interactions in Tumorigenesis and Breast Cancer
DOI: http://dx.doi.org/10.5772/intechopen.88128
vascularization, and it is not clear if comorbidities favoring increased quantities of 
mast cells may improve tumor vascularization and metastasis.
3.1.5 Macrophages
Macrophages are mononuclear phagocytic cells that according to environment 
signals turn into different phenotypes. One of these phenotypes is the classically 
activated macrophages or M1, induced by Toll-like receptors (TLR) and IFN-γ. These 
cells are characterized by the expression of IL-12, the major histocompatibility com-
plex class II (MHC-II) and TNF-α, and ROS and nitric oxide (NO) production and 
are associated with microorganisms and cell destruction [94]. The second phenotype 
is the “alternatively or selectively” activated macrophages, which are characterized 
by the secretion of IL-4, IL-10, IL-13, and TGF-β and the expression of arginase-1 
and VEGF and are related to wound healing and humoral response [94, 95].
Macrophages, monocytes, and DC can be found in tumor microenvironment, 
being the macrophages the most abundant phagocytic population. Tumor-
associated macrophages (TAMs) are characterized by the cell surface expression 
of CD68 and have been related to invasion and migration of cancer cells, being 
a prognostic factor in cancer [95, 96]. Some reports have shown that the density 
of TAMs in breast cancer samples is related to hormone receptor status, lymph 
node metastasis, stage, and prognosis. Higher concentrations of TAMs are associ-
ated with a poor prognosis, and the worse prognostic group is the one with a high 
proportion of CD163 and CD206 (M2 markers) [95].
TAMs are related to immunosuppressive features, for example, low antigen-
presenting capability, low tissue remodeling activity, and low toxicity functions 
that promote tumor growth and metastasis [97]. These immunosuppressive TAMs 
function as M2 macrophages and are activated by IL-4, IL-10, IL-13, glucocorti-
coids, and vitamin D3 [98].
3.1.6 NK cells
The innate immune system recognizes and kills infected and transformed cells; 
NK cells are responsible for this task, through granzyme b-perforin system, TNF-
related apoptosis-inducing ligand (TRAIL), and the expression of CD95 ligand 
[99]. NK cells produce IFN-γ, granulocyte/macrophage colony-stimulating factor 
(GM-CSF), and TNF [100] and are one of the main cells in antitumoral response.
Depending on the signals that NK cells receive, activation or inhibition receptors 
or coreceptors are expressed [101, 102].
NK cell cytotoxicity is activated by different ligands upregulated during cellular 
stress, also with the recognition of antibodies in the antibody-dependent cellular 
toxicity (ADCC) through the expression of CD16 (Fc immunoglobulin fragment 
low-affinity receptor) and with the detection of cells that underexpressed HLA-
class I molecules [101, 103]. In immunosurveillance, tumor cells are detected and 
destroyed by NK cells, through these mechanisms (Figure 2). In immunosubver-
sion, tumor cells evade NK cell recognition, and tumor microenvironment leads to 
NK cell impairment, through the inhibition of surface-activating receptor expres-
sion, such as NKp46 and NKG2D or NKp30 and NKG2D mediated by indoleamine 
2,3-dioxygenase (IDO) and TGF-β1, respectively (Figure 2) [101, 104, 105].
In breast cancer patients, tumor NK cells possess a more prominent inhibitory 
phenotype than peripheral NK cells. Also depending on disease progression, for 
example, in late stages, NK cells lose their cytotoxic activity and express inhibitory 
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receptors (NKG2A); meanwhile, in early stages NK cells express activating recep-
tors (NKp30, NKG2D, DNAM-1, and CD16). One of the stroma-derived suppressor 
factors that induced NK cell function impairment is TGF-β1 [101].
3.2 Immune adaptive cells in mammary tumors
3.2.1 T lymphocytes
T lymphocytes are one of the most important cell populations in cancer. The 
activation of T cells is performed, firstly, through TCR stimulation with its specific 
antigen, presented in the context of MHC, by a dendritic cell or another professional 
antigen-presenting cell; secondly, with the binding of “costimulatory” molecules in 
the dendritic cell; and, thirdly, by the cytokine milieu and soluble factors [106, 107]. 
In addition, antigen presentation is performed by immature DCs, resulting in a  
non-responsive or anergic T cells [108]. In breast cancer tertiary lymphoid structures 
and germinal centers were detected next to tumor in extensively infiltrated tumors. 
This TLS possesses a similar structure to lymph node, including a T-cell zone with 
CD3+/CD4+ T cells and a germinal center with B cells and T follicular helper (Tfh) 
cells [109].
3.2.2 T helper cells
Different factors such as the expression of transcription factors, chemokine 
receptors, signal transduction activators, and the chemokine and cytokine secre-
tion regulate the effector phenotype and function of these cells [107]. Regarding 
human breast cancer, different effector phenotypes have been reported, for example, 
through flow cytometry of invasive breast tumors, Tfh, Th1, Th2, Th17, and Tregs 
were found [109].
3.2.3 T follicular helper (Tfh) cell
The effector phenotype Tfh cell stays in the lymph node and induces activa-
tion and differentiation of affine B cells into plasma or memory cells [110]. But, in 
advanced stages of invasive breast cancer, CD4+ Tfh cells were detected in the T-cell 
zone and germinal centers of TLS. This localization is may be due to their function 
in tumor, because Tfh cells were localized near to B cells [111].
3.2.4 T helper 1 (Th1)
CD4+ T helper 1 (Th1) cell differentiation and IFN-γ production are modulated 
by IL-12 produced by APCs (monocytes/macrophages, DCs, and even NK cells) and 
IFN-γ (Figure 2) [112–114]. Th1 cells express the transcription factor T-bet; secrete 
IFN-γ, TNF-α, and IL-2; and function as regulators of monocyte activation and T 
lymphocyte differentiation induction [115, 116]. Th1 cells are associated with early 
tumor phases, because of their IFN-γ production that activates CD8+ cytotoxic T 
cells (Figure 2) [117]. Therefore, there is an association between improving survival 
and the infiltration of Th1 and CD8+ T cells in breast tumors [118].
3.2.5 T helper 2 (Th2)
A T helper subset related to immunosubversion and tumor progression is the 
CD4+ T helper 2 (Th2) cells, characterized by the expression of transcription factor 
GATA3 and the secretion of IL-4, IL-5, IL-10, and IL-13 [121]. Th2 cells are related to 
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nematode response, tissue repair, and antibody production. In breast cancer, Th2 cells 
have been found in human mammary tumors [109], and IL-13 is reported to be present 
also in human breast tumors, promoting tumor development (Figure 2) [119].
3.2.6 T helper 17 (Th17)
CD4+ Th17 (T helper 17) cells are related to autoimmunity, tissue inflamma-
tion, and host defense against bacteria, fungi, viruses, and protozoa and play an 
important role in mucosal immunity [120]. Th17 cells produce IL-17 and IL-22 and 
express transcription factor RORγt [121]. Regarding Th17 cells in tumor, it is not 
recognized if they could be induced in tumor or be recruited from other places, but 
their presence has been detected in breast tumors [109]. Th17 cell tumor infiltration 
mediates an inflammatory microenvironment [122].
3.2.7 Regulatory T cells (Tregs)
Tregs are a subset of T helper cells that express Foxp3 transcription factor and 
have an important role in controlling inflammation and autoimmunity in mouse 
and man [123]. These cells normally are residents in the secondary lymphoid 
organs, lung, peripheral blood, gastrointestinal tract, liver, and skin and can 
be recruited to other tissues, under inflammatory conditions [124]. Tregs are 
CD4+, CD127low, CD25hi, and also CTLA+ and exert immune suppression through 
different mechanisms, for example, the production of tolerogenic cytokines 
(IL-10, IL-35, and TGF-β), the induction of arginine depletion that leads to T-cell 
dysfunction, the expression of suppressive molecules (CTLA-4, CD80/CD86), 
and the direct cytolysis through granzyme b-perforin system and through local 
consumption of IL-2 (with the constitutive expression of high-affinity receptor 
CD25) [125, 126].
IL-10 is a suppressive cytokine secreted by macrophages, NK cells, NKT cells, B 
cells, DCs, and CD4+ T cell (specially Treg cells), that suppress inflammatory responses, 
prevent autoimmune diseases, and enhance tumor growth (Figure 2) [127–129].
3.2.8 T cytotoxic lymphocytes (CTLs)
CD8+ cytotoxic T lymphocytes play an important role in adaptive antitumor 
response; therefore, when tumor immunosubversion is stablished, the cytotoxicity 
of CD8+T cells gets compromised (Figure 2). During immunosurveillance, in sec-
ondary lymphoid organs (lymph nodes and spleen), APCs present tumor-associated 
antigens and tumor neoantigens to CTLs, which in the presence of costimulatory 
and cytokine signals, such as IL-12 (produced by DCs) and IFN-γ (produced by Th1 
cells), undergo activation, maturation, and clonal expansion [117, 130]. After, CTLs 
migrate through the body, search for specific antigen, and kill the tumor antigen-
specific cell through IFN-γ release and perforin and granzyme system (Figure 2) 
[117, 131, 132]. Also, through the activation of its receptor, IL-12 promotes the 
differentiation of effector CD8 cells and inhibits at the same time the development 
of memory CD8 cells [133, 134]. When effector CTL cells failed in killing target cell 
and are exposed to persistent antigen stimulation (in chronic infectious diseases or 
in tumors), CTL express inhibitory cell surface receptors, PD-1, LAG3, TIM3, TIGIT, 
and CTLA-4, and became exhausted CD8+ T cells. During tumor immunosubversion 
CD8+ T cell exhausted profile is generated; therefore, cytolysis or IFN-γ secretion 
mediated through CTLs is inhibited (Figure 2) [135].
Another important cytokine related to CD8+ T cells is IL-2, which is described 
not only as a growth factor, secreted by CD4+- and CD8+-activated T cells, but also 
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as a differentiation inducer for CD8+ effector cells [115]. CD8+ T cells cultured with 
IL-2 presented an upregulation in perforin (Prf1) transcription and a suppressed 
expression of Bcl6 and IL-7Rα (memory CD8+ markers). Meanwhile, in CD8+ T 
cells with deficiency of IL-2 receptor (IL-2Rα or CD25), cell differentiation impair-
ment was shown in vivo, demonstrated with granzyme B and perforin diminished 
expression and a poor ex vivo cytotoxicity [136].
In regard to CD8+ T cell antitumor activity, an experiment in tumor from four T1 
mammary gland tumor cells in syngeneic mice showed that in mice injected with 
IL-12, tumor growth was suppressed through an increased CD8+ cell infiltration 
and production of IFN-γ and the induction of apoptosis of tumor cells [137]. This 
effect correlates with good prognosis in CD8+ T cell infiltration in breast tumors in 
women [138]. With the time, CTLs lose their cytotoxic phenotype and acquired an 
exhausted phenotype that needs further characterization in breast tumors but is 
likely to be associated with late stages (triple-negative breast cancer).
4. Endocrine factors related to the development of breast cancer
Mammary gland epithelium is highly dynamic, characterized by proliferation, 
differentiation, and apoptosis cycles, regulated in part by hormones. Breast cancer 
is associated with an abnormal proliferation of epithelial cells, related to genetic 
mutations and epigenetic modifications in suppressor and DNA repair genes and 
oncogenes [139].
4.1 Estrogens and progesterone
During life, the mammary gland development is divided by different stages and 
modulated by hormones such as estrogens (17β estradiol) and progesterone. These 
stages are related to sexual development and includes embryonic and prepuberal 
phase, puberty, pregnancy, lactation, and involution. Epidermal growth factor 
(EGF) and estrogens that arrive through the breast stroma during puberty induce 
ductal elongation and branching. Meanwhile, the lobes formed by secretory epi-
thelial cells organized in alveoli develop during gestation and probably in lactation, 
through the placental lactogens, progesterone, and prolactin signaling [140]. In 
lactation, milk secretion is promoted by the contraction of rounding epithelium 
smooth muscle cells mediated by oxytocin [8].
Estrogen effects are regulated through alpha and beta estrogen receptors (ERα 
and ERβ), both expressed in mammary normal tissue [141]. ERα signaling is 
responsible for ductal elongation in puberty and the stromal invasion in normal 
breast tissue [142].
The sharing ERα-ERβ distribution suggests that ERβ may be related to a nega-
tive ERα regulation, through antiestrogen or non-habitual effects [143]. The ERα 
or ERβ receptor dimerization is induced by ligand-receptor union and leads to the 
formation of homodimers (ERα/α, Erβ/β) or heterodimers (ERα/β). Recently, it was 
described that the dimer conformation is associated with their function. ERα/α is 
linked with proliferation induced by estrogen, and ERβ/β homodimer is linked with 
antiproliferative and pro-apoptotic functions; meanwhile, ERα/β effects are not 
elucidated as well (Figure 3) [144].
Proliferation in breast tumor cells is ligand-dependent in early stages and 
ligand-independent in late stages. In the estrogen-dependent pathway, cell 
proliferation is activated through cytoplasmic or membrane estrogen receptors. 
Intracellular signaling begins with estrogen-receptor union, their consequent 
translocation to nuclei, where the estrogen-receptor complex binds to specific 
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estrogen-response elements in estrogen-responsive genes or to other transcription 
factors, such as AP1 or Sp1, in a non-ERE way, functioning as gene transcription 
co-regulator [145, 146]. Furthermore, estrogen-membrane ER signals through 
GPR30 and Erk to elicit proliferation (Figure 3) [145]. Meanwhile, the estrogen-
independent pathway is mediated through ligand binding and activation of 
growth factor receptors (GFRs), such as epithelial growth factor receptor (EGFR), 
insulin-like growth factor receptor (IGF), and HER-2, among others. This activa-
tion promotes ER phosphorylation and activation through PI3K/AKT and Ras/Raf/
MAPK pathways [145, 147].
On the other hand, progesterone exerts its action through two receptors (PRA 
and PRB), both signaling and activating gene transcription [148]. ERα and PR are 
co-expressed in the mammary gland in 15–30% of epithelial cells [149]. Meanwhile, 
estradiol and progesterone drive epithelial mammary gland proliferation directly 
through the hormone-receptor union and have been proposing a second control 
mechanism in which epithelial cells sense hormone concentrations through their 
estrogen and progesterone receptors and, in consequence, secrete or not growth 
factors to promote nearby cell proliferation [148].
In breast cancer staging, ER and/or PR expression loss is associated with more 
aggressive tumors, with self-sufficiency of growth signals independently of estro-
gen or progesterone receptors. Additionally, positive ERα tumor is related to a better 
prognostic, as well as ERβ tumor expression [150].
Figure 3. 
Endocrine interactions in breast cancer. In the estrogen-dependent pathway, cell proliferation is activated 
through cytoplasmic or membrane estrogen receptors. Intracellular signaling begins with estrogen-receptor 
union, their consequent translocation to nuclei, where the estrogen-receptor complex binds to specific estrogen-
response elements (ERE) in estrogen-responsive genes, in a non-ERE way, functioning as gene transcription 
co-regulator. Furthermore, estrogen-membrane ER signals through GPR30 and Erk to elicit proliferation. 
Estrogen sources to breast tumor cell are intracrine, endocrine (blood supply), and paracrine (stromal adjacent 
cells). Dehydroepiandrosterone (DHEA) and other androstenes inhibit tumor cell proliferation.
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Besides the receptor’s presence in tumor cells, another important issue to 
consider is the hormone levels within the tumor. Intratumoral estradiol concentra-
tion in normal breast tissue was lower than in ductal carcinoma in situ and invasive 
ductal carcinoma [151].
In this regard, aromatase is an important enzyme responsible for the production 
of estrogens, estrone, and estradiol, through the aromatization and conversion 
of androstenedione and testosterone [152]. Invasive ductal carcinoma expresses a 
higher amount of aromatase mRNA than DCIS and normal breast tissue, and both 
epithelial and stromal cells expressed aromatase mRNA [151]. Therefore, tumor 
cells have different sources of estrogen, called endocrine (ovary), intracrine, and 
paracrine, which enhance cell proliferation of tumor target cells.
4.2 Androgens
Meanwhile estrogens stimulate mammary gland development, and androgens 
inhibit it. For example, estrogen treatment in prostate cancer patients promotes 
mammary gland growth and ingestion of androgens by athletes or transsexuals and 
produces mammary gland atrophy [153].
Androgens as testosterone (T) and dihydrotestosterone (DHT) exert their effects 
through the union to their androgen receptor (AR). This receptor has been colocal-
ized with ER and PR in mammary gland epithelia, but not in adjacent stromal cells; 
therefore, androgen-mediated proliferation is regulated in the mammary epithelium 
[154]. The androgen receptor (AR) has been reported to be present in 80% of 
primary breast tumors, and its presence is associated with a favorable response to 
endocrine treatment and a better prognostic, especially if ER is also present [155].
In this sense, the union of BRCA1 gene product with AR activates AR functions; 
therefore, the mutation of this BRCA1 may interfere with AR antiproliferative func-
tions and allow cell proliferation [156].
4.3 Adrenal steroids
Dehydroepiandrosterone, an estrogen and testosterone precursor [157], 
is an adrenal steroid which is metabolized into active metabolites, such as 
Δ5-androstene-3β, 17β-diol (17β-androstenediol), Δ5-androstene-3β17α-diol 
(17α-androstenediol), and Δ5-androstene-3β,7β,17β-triol (17β-androstenetriol) 
[158]. DHEA is able to activate ERα, ERβ, AR, and glucocorticoid receptor (GR); 
meanwhile, its metabolites showed a weaker activation [159]. All of androstene hor-
mones (DHEA, 17β-androstenediol, 17α-androstenediol, and 17β-androstenetriol) 
have been shown to have an antiproliferative effect in cellular lines, including breast 
cancer (Figure 3) [160]. Only DHEA presented a protective effect in vivo, but the 
other androstenes have not been tested in vitro [160]; therefore, there is a promis-
ing search field around androstenes and the development of breast cancer.
5. Tumor development and neuroimmunoendocrine interactions
The relation between nervous and immune systems is importantly transduced 
through β2AR and GCR localized in immune cells, such as B lymphocytes, T 
lymphocytes, NK cells, and macrophages, which regulate cytokine production, 
molecule expression, development, survival, proliferation, circulation, and cell 
recruitment [161]. Meanwhile, interactions among endocrine and immune or 
nervous systems are regulated through the hormone receptor expression (ER, PR, 
and AR) and the effects driving in immune and/or nervous cells (Figure 4).
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In mice treated with selective β2AR agonists, such as clenbuterol or salbutamol, 
to stimulate these receptors, the lymph node egress of CD4+, CD8+ T lympho-
cytes, and antigen-primed T cells and B cells is retarded and is associated with 
lymphopenia. This lymphocyte retention is mediated through CXC chemokine 
receptor 4 (CXCR4) in T cells and B cells and is thought to explain the reduction of 
T-cell-mediated inflammation and lymphopenia [161]. CXCR4 is also expressed in 
monocytes and dendritic cells. CXCR4 ligand is the stromal cell-derived factor 12 
(CXCL12), and both are linked to breast cancer metastasis. CXCR4-CXCL12 union 
promotes cell migration and adhesion and angiogenesis [162].
In lymph nodes with breast cancer metastasis, an increased level of CXCR4 
transcript was detected compared to nonmetastatic lymph nodes. Also, a higher 
mRNA expression was found in breast cancer tumor stages III–IV than in stages 
I–II. Interestingly, in tumor tissues with HER-2 expression, CXCR4 transcription 
levels are also more elevated than in HER-2-negative tumors; therefore, there is a 
positive correlation between CXCR4 and HER-2 expression in breast tumors [163]. 
This phenomenon is explained because HER-2 enhances and impedes CXCR4 
degradation [164]. CXCR4-CXCL12 axis is evolved in organ-directed metastasis, 
mainly associated with a higher CXCL12 expression in lymph nodes and lung, liver, 
and bone tissues where breast cancer metastasis is very common. CXCL12 acts as a 
chemoattractant for breast cancer cells that express CXCR4, promoting the arrival 
of these cells [165, 166].
Another group of immune cells, in which β2AR produces an inhibitory effect, is 
the DCs. The stimulation of β2AR with salbutamol inhibited the NF-κB transcrip-
tion [167]. This transcription factor is required for DC antigen presentation; for the 
expression of CD80, CD86, and CD40 (costimulatory molecules); and for IL-12 
secretion [168]. Also, salmeterol (β2AR agonist) diminishes the IL-1, IL-6, and 
TNF-α production, in LPS-activated DCs [169].
On the other hand, in human monocytes primed during 16 hours with IFN-γ 
and stimulated with LPS, the addition of salbutamol diminished the IL-12 and 
TNF-α secretion, but not the IL-1α, IL-1β, or IL-10 production. Also, in neonatal 
CD4+ lymphocytes, the Th1 cell differentiation in vitro was inhibited; instead, these 
CD4+ T cells, stimulated with β2AR agonists, produce IL-4 (Th2 cytokine), but not 
Figure 4. 
Neuroimmunoendocrine interactions in breast cancer. Bidirectional interactions among nervous, immune, and 
endocrine systems are stablished by soluble factors and receptors in cells of the three systems.
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IFN-γ (Th1 cytokine) [168]. Meanwhile in rats, adrenaline or metaproterenol (β2AR 
agonist) in physiologic doses inhibited NK cell activation [170].
Either by directly action on tumor or immune cells, sympathetic signals regulate 
tumor progression. In this regard, as mentioned before, immune cell recruitment is 
a crucial step in immunosurveillance and immunosubversion. Sympathetic innerva-
tion in distant organs such as bone marrow promotes noradrenaline secretion that 
activates bone marrow-resident cells and promotes immune cell development and 
trafficking [171] and the posterior cell recruitment to tumor microenvironment 
mediated through tumor chemokine release and chemokine receptor expression in 
immune cells [166]. In this sense, tumor primary macrophage recruitment [39] and 
tumor cells increasing cytokine pro-inflammatory expression [21] are β2AR medi-
ated and influencing tumor progression [37, 39].
Despite the differences in β2AR breast tumor cell expression that as an example 
in MB-231 cell line is higher than in MB-231BR cell line, the treatment with a  
β2AR agonist (terbutaline or norepinephrine) modulates VEGF secretion through 
cAMP-PKA pathway, which is diminished in MB-231 cell line and augmented in 
MB-231BR cell line (metastatic to mouse brain). Meanwhile, IL-6 production in 
both cell lines was increased, in a cAMP-dependent and PKA-independent pathway 
[21]. These differences in VEGF secretion are maybe associated with the brain 
metastatic potential of MB-231BR cell line, because VEGF enhances blood vessel 
neoformation for tumor growth.
As mentioned before, immunosuppressive TAM works as M2 macrophages and, 
in this sense, has been found that epinephrine induces M2 macrophage polarization, 
in RAW 264.7 cells. This polarization is regulated through β2AR. Also, in breast 
tumors co-expression of CD163+ (M2 macrophages human marker) and β2AR 
cell has been demonstrated; thus, macrophages in tumor microenvironment are 
influenced by adrenergic signals [37]. The relationship between M1 or M2 macro-
phages and hormone receptor status in breast cancer is due to the development of 
the disease. Hollmen et al. reported that when a cell line positive for the estrogen 
receptor (ER) is co-cultured with human monocytes, they acquire an M1 pheno-
type; meanwhile, the co-culture of them with ER- breast cancer cell line induced 
an M2 phenotype. The above indicates that ER governs the changes of the macro-
phages phenotype [172]. ER+ breast cancer is related with an “early” development 
and a better prognostic, maybe associated with a M1 acute phase inflammatory 
response that effectively controls tumor progression. Meanwhile, TNBC usually 
presents a worse prognosis, and the presence of M2 exerts an immunosuppressive 
intratumoral effect that allows breast tumor growth and metastasis. Therefore, the 
macrophage phenotype is due to microenvironmental conditions and is associated 
consequently with tumor staging and prognosis.
Overexpression of HER-2 is correlated with β2AR expression levels in breast 
tumor samples. In this sense, in MCF-7 cells overexpressing HER-2 (MCF-7/
HER-2), β2AR expression was also elevated, in an autocrine way through MCF-7/
HER-2 epinephrine secretion. Interestingly, β2AR activation with epinephrine, 
with norepinephrine, or with β2AR agonists (isoproterenol and salmeterol) induces 
HER-2 expression in MCF-7 breast cancer cells. These findings are important 
because in HER-2+ breast cancer cells, the activation of this surface tyrosine kinase 
may improve epinephrine secretion, through ERK signaling. Epinephrine may 
upregulate either β2AR expression or HER-2 [173].
Concerning to breast cancer, in more aggressive tumors (TNBC), an increased 
amount of Foxp3+ lymphocytes can be found in than less aggressive tumors (ER+ or 
HER+ tumors); this higher Treg tumor infiltration is also related to an increased risk 
of recurrence and a poor prognosis [174].
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Ali et al. reported that in ER− and HER+ breast tumors, CD8+ cell infiltration in 
tumor was associated with a reduction (28%) of mortality risk, but if these cells were 
in the tumor stroma, the risk reduction was lower (21%). A similar risk reduction 
(27%) was found in ER+/HER+ breast tumors [138]. The CD8+ T-cell presence in tumor 
is associated then with the induction of tumor cell apoptosis that improve the progno-
sis and in some point is still acting as an effector-killing cell rather than a memory cell.
6. Conclusion
In breast cancer development, tumor cell proliferation is extensively studied, 
and almost all the treatments are encouraged to diminish it. Tumor cell interactions 
with other immune, nervous, tumor, and stromal cells, through the production of 
soluble factors and the expression of receptors, are the drivers of this proliferation. 
These relations may be driven inside the tumor or across the organism in distant 
places that respond to tumor signals. Therefore, elucidating not only molecular 
mechanisms but interactions among cells may enhance the development of new and 
more effective therapies against breast cancer.
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